CD19 and infection: One of the key factors that has permitted the successful clinical development of anti-CD19 CAR T-cell therapy is the fact that the CD19 antigen is exclusively expressed on cells of the B-lymphocyte lineage, and even complete ablation of the B-cell compartment can be managed with intravenous immunoglobulin replacement, which minimises the risk of infection with encapsulated bacteria.